Pam Klein
Impact in
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Papers in
- Co-authors
- David Albert Ramies (2 shared papers)Vincent A. Miller (2 shared papers)David H. Johnson (2 shared papers)Roy S. Herbst (2 shared papers)Bruce Evan Johnson (2 shared papers)Mark G. Kris (1 shared paper)Hai T. Tran (1 shared paper)Lou Fehrenbacher (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Genetics in Medicine (1 paper)Breast Cancer Research and Treatment (1 paper)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Pam Klein
5 papers receiving 2.6k citations
Pam Klein's Hit Papers
Peers
Comparison fields: 5 of 72
- Pulmonary and Respiratory Medicine 1.9k
- Oncology 1.5k
- Cancer Research 350
- Molecular Biology 634
- Pathology and Forensic Medicine 151
Countries citing papers authored by Pam Klein
This map shows the geographic impact of Pam Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pam Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pam Klein more than expected).
Fields of papers citing papers by Pam Klein
This network shows the impact of papers produced by Pam Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pam Klein. The network helps show where Pam Klein may publish in the future.
Co-authors
The 25 scholars most cited alongside Pam Klein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 1284 |
| 2 | Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib Hit paper breakdown → | 2005 | 1273 |
| 3 | 2002 | 149 | |
| 4 | 2007 | 61 | |
| 5 | 2021 | 24 |
About Pam Klein
Pam Klein is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Insect Science and Renewable Energy, Sustainability and the Environment, having authored 5 papers that have together received 2.8k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (1 paper), Colorectal Cancer Treatments and Studies (1 paper) and Lung Cancer Treatments and Mutations (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.9k citations), Oncology (1.5k citations), Cancer Research (350 citations), Molecular Biology (634 citations) and Pathology and Forensic Medicine (151 citations). Pam Klein has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include David Albert Ramies, Vincent A. Miller, David H. Johnson, Roy S. Herbst, Bruce Evan Johnson, Mark G. Kris, Hai T. Tran, Lou Fehrenbacher, Diane Prager and Xin Li. Their work appears in journals such as Journal of Clinical Oncology, Genetics in Medicine and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.